What is Quantum Genomics?
Quantum Genomics, established in 2005 and headquartered in Paris, France, is dedicated to advancing cardiovascular medicine. The company's core focus lies in the development of a proprietary class of drugs targeting brain aminopeptidase A inhibition (BAPAI). This innovative approach aims to address unmet needs in the treatment of cardiovascular diseases, positioning Quantum Genomics as a key player in the biopharmaceutical innovation landscape. The company's commitment to research and development is evident in its pursuit of novel therapeutic solutions.
How much funding has Quantum Genomics raised?
Quantum Genomics has raised a total of $18.3M across 3 funding rounds:
Debt
$1.8M
Stock Offering
$16M
Other Financing Round
$539K
Debt (2021): $1.8M with participation from Bpifrance
Stock Issuance/Offering (2022): $16M, investors not publicly disclosed
Other Financing Round (2024): $539K, investors not publicly disclosed
Key Investors in Quantum Genomics
Bpifrance
Bpifrance is a French public investment bank established in 2012, dedicated to financing companies across all development stages with credit, guarantees, and equity. They actively support innovation, international expansion, and export activities for startups, SMEs, and mid-cap companies.
What's next for Quantum Genomics?
With the recent influx of $539K in strategic capital, Quantum Genomics is poised for an accelerated growth phase. This significant backing, part of its $18.3M in total financing, will likely be directed towards advancing its BAPAI-based cardiovascular drug candidates through critical clinical trials and regulatory processes. The company may also explore strategic partnerships or expand its research capabilities to further solidify its market position. The enterprise-level funding suggests a focus on scaling operations and preparing for potential commercialization, marking a pivotal moment in Quantum Genomics' trajectory.
See full Quantum Genomics company page
